|
11
|
1 #{"column_names":["contig","pos","ref","rPos","trns","pep","AA1","loc","AA2","KEGG","pred","path"],"pos":2,"rPos":4,"ref":3,"dbkey":"canFam2","scaffold":1,"species":"bear","kegg_gene":10,"kegg_path":12}
|
|
|
2 Contig39_chr1_3261104_3261850 414 chr1 3261546 ENSCAFT00000000001 ENSCAFP00000000001 S 667 F 476153 probably damaging cfa00230=Purine metabolism.cfa00500=Starch and sucrose metabolism.cfa00740=Riboflavin metabolism.cfa00760=Nicotinate and nicotinamide metabolism.cfa00770=Pantothenate and CoA biosynthesis.cfa01100=Metabolic pathways
|
|
|
3 Contig62_chr1_19011969_19012646 265 chr1 19012240 ENSCAFT00000000144 ENSCAFP00000000125 * 161 R 483960 probably damaging N
|
|
|
4 Contig36_chr1_20102654_20103213 365 chr1 20103029 ENSCAFT00000000160 ENSCAFP00000000140 R 407 Q 610160 possibly damaging N
|
|
|
5 Contig136_chr10_3710404_3714591 3079 chr10 3713499 ENSCAFT00000000215 ENSCAFP00000000194 T 103 P U benign N
|
|
|
6 Contig36_chr1_23682012_23682647 374 chr1 23682388 ENSCAFT00000000233 ENSCAFP00000000210 N 234 S 483973 benign N
|
|
|
7 Contig163_chr10_4573526_4574494 487 chr10 4574010 ENSCAFT00000000365 ENSCAFP00000000332 R 186 K 474414 benign cfa00450=Selenocompound metabolism.cfa00970=Aminoacyl-tRNA biosynthesis
|
|
|
8 Contig55_chr1_40056604_40059808 2081 chr1 40058686 ENSCAFT00000000507 ENSCAFP00000000458 I 247 K 484023 possibly damaging N
|
|
|
9 Contig17_chr1_40203628_40205630 1417 chr1 40205044 ENSCAFT00000000517 ENSCAFP00000000468 N 109 S 476233 benign N
|
|
|
10 Contig97_chr1_44847984_44848380 285 chr1 44848272 ENSCAFT00000000674 ENSCAFP00000000618 Q 27 R 611986 benign N
|
|
|
11 Contig214_chr10_16106753_16106969 121 chr10 16106873 ENSCAFT00000000724 ENSCAFP00000000668 A 301 T 609478 benign N
|
|
|
12 Contig75_chr1_45731970_45732932 436 chr1 45732397 ENSCAFT00000000760 ENSCAFP00000000701 I 490 V U benign N
|
|
|
13 Contig33_chr1_45614845_45617413 1835 chr1 45616685 ENSCAFT00000000760 ENSCAFP00000000701 A 4390 V U benign N
|
|
|
14 Contig95_chr10_18829724_18831056 914 chr10 18830645 ENSCAFT00000000762 ENSCAFP00000000703 A 512 V U possibly damaging N
|
|
|
15 Contig197_chr13_8622062_8623071 606 chr13 8622665 ENSCAFT00000001047 ENSCAFP00000000959 T 406 I 475067 possibly damaging cfa00240=Pyrimidine metabolism.cfa00410=beta-Alanine metabolism.cfa00770=Pantothenate and CoA biosynthesis.cfa00983=Drug metabolism - other enzymes.cfa01100=Metabolic pathways
|
|
|
16 Contig243_chr10_19959210_19960069 701 chr10 19959858 ENSCAFT00000001052 ENSCAFP00000000964 E 1345 K U benign N
|
|
|
17 Contig137_chr13_10622950_10624043 1039 chr13 10623979 ENSCAFT00000001063 ENSCAFP00000000975 E 10 K 481999 benign N
|
|
|
18 Contig137_chr13_10622950_10624043 1006 chr13 10623946 ENSCAFT00000001063 ENSCAFP00000000975 R 21 C 481999 probably damaging N
|
|
|
19 Contig115_chr12_4411478_4412322 124 chr12 4411614 ENSCAFT00000001076 ENSCAFP00000000986 R 177 H U benign N
|
|
|
20 Contig150_chr12_4438230_4439944 385 chr12 4438614 ENSCAFT00000001104 ENSCAFP00000001014 Y 277 D 607591 benign N
|
|
|
21 Contig84_chr1_52076858_52077103 80 chr1 52076943 ENSCAFT00000001141 ENSCAFP00000001046 C 147 Y 484064 benign N
|
|
|
22 Contig29_chr13_13215547_13217183 793 chr13 13216352 ENSCAFT00000001146 ENSCAFP00000001050 P 1 R 475076 probably damaging N
|
|
|
23 Contig251_chr10_22876556_22877097 152 chr10 22876714 ENSCAFT00000001204 ENSCAFP00000001103 E 1162 D 481203 benign N
|
|
|
24 Contig21_chr10_22964856_22965302 202 chr10 22965058 ENSCAFT00000001219 ENSCAFP00000001115 P 6 Q 474465 benign N
|
|
|
25 Contig199_chr12_5083018_5084534 453 chr12 5083472 ENSCAFT00000001250 ENSCAFP00000001144 I 185 T 481729.481731 benign N.cfa04145=Phagosome.cfa04514=Cell adhesion molecules (CAMs).cfa04612=Antigen processing and presentation.cfa04672=Intestinal immune network for IgA production.cfa04940=Type I diabetes mellitus.cfa05140=Leishmaniasis.cfa05145=Toxoplasmosis.cfa05150=Staphylococcus aureus infection.cfa05152=Tuberculosis.cfa05164=Influenza A.cfa05166=HTLV-I infection.cfa05168=Herpes simplex infection.cfa05310=Asthma.cfa05320=Autoimmune thyroid disease.cfa05322=Systemic lupus erythematosus.cfa05323=Rheumatoid arthritis.cfa05330=Allograft rejection.cfa05332=Graft-versus-host disease.cfa05416=Viral myocarditis
|
|
|
26 Contig41_chr13_21629998_21630487 161 chr13 21630157 ENSCAFT00000001352 ENSCAFP00000001239 P 729 S 482026 possibly damaging cfa00565=Ether lipid metabolism
|
|
|
27 Contig16_chr13_21786766_21788016 169 chr13 21786927 ENSCAFT00000001363 ENSCAFP00000001249 V 1142 A 475084 benign cfa03022=Basal transcription factors
|
|
|
28 Contig60_chr1_60333035_60333884 731 chr1 60333755 ENSCAFT00000001421 ENSCAFP00000001307 V 400 I 484096 benign N
|
|
|
29 Contig44_chr13_24555640_24556298 499 chr13 24556139 ENSCAFT00000001523 ENSCAFP00000001400 N 660 S 475088 benign N
|
|
|
30 Contig153_chr12_5955114_5958935 2950 chr12 5958094 ENSCAFT00000001575 ENSCAFP00000001449 E 13 D 481744 benign cfa04141=Protein processing in endoplasmic reticulum
|
|
|
31 Contig146_chr13_25076435_25077249 723 chr13 25077165 ENSCAFT00000001587 ENSCAFP00000001461 T 9 S 482035 benign N
|
|
|
32 Contig81_chr13_25579918_25582207 874 chr13 25580772 ENSCAFT00000001597 ENSCAFP00000001469 E 62 G 609411 benign N
|
|
|
33 Contig159_chr10_28604683_28606028 753 chr10 28605433 ENSCAFT00000002056 ENSCAFP00000001903 S 79 P 610014 benign N
|
|
|
34 Contig30_chr11_29945215_29949829 3973 chr11 29949181 ENSCAFT00000002100 ENSCAFP00000001944 M 282 T U benign N
|
|
|
35 Contig102_chr10_29039231_29041280 829 chr10 29040065 ENSCAFT00000002110 ENSCAFP00000001953 R 311 Q 481249 unknown N
|
|
|
36 Contig187_chr1_78583588_78584279 250 chr1 78583839 ENSCAFT00000002175 ENSCAFP00000002014 K 176 R 476310 benign N
|
|
|
37 Contig199_chr1_79234891_79237527 384 chr1 79235278 ENSCAFT00000002259 ENSCAFP00000002095 V 403 A 484151 benign N
|
|
|
38 Contig119_chr12_12212738_12214663 1005 chr12 12213720 ENSCAFT00000002460 ENSCAFP00000002280 R 749 Q 481785 possibly damaging N
|
|
|
39 Contig119_chr12_12212738_12214663 918 chr12 12213633 ENSCAFT00000002460 ENSCAFP00000002280 R 778 Q 481785 benign N
|
|
|
40 Contig39_chr14_10730123_10732539 335 chr14 10730462 ENSCAFT00000002537 ENSCAFP00000002356 V 1179 E U benign N
|
|
|
41 Contig41_chr1_84886710_84894794 3494 chr1 84890207 ENSCAFT00000002577 ENSCAFP00000002394 E 1089 K 484157 possibly damaging N
|
|
|
42 Contig182_chr12_13881114_13883427 1690 chr12 13882828 ENSCAFT00000002578 ENSCAFP00000002395 S 99 G 608906 benign N
|
|
|
43 Contig34_chr11_48151988_48152712 198 chr11 48152205 ENSCAFT00000002660 ENSCAFP00000002468 C 587 R U possibly damaging N
|
|
|
44 Contig37_chr10_34118256_34119269 437 chr10 34118687 ENSCAFT00000002792 ENSCAFP00000002588 A 377 T 474523 benign N
|
|
|
45 Contig21_chr14_16091274_16093278 716 chr14 16091997 ENSCAFT00000002849 ENSCAFP00000002642 R 126 C 475216 probably damaging N
|
|
|
46 Contig57_chr1_90983602_90984717 559 chr1 90984158 ENSCAFT00000002999 ENSCAFP00000002781 A 226 V U benign N
|
|
|
47 Contig45_chr12_15798569_15798849 141 chr12 15798709 ENSCAFT00000003163 ENSCAFP00000002938 N 342 S 474921 benign cfa03040=Spliceosome
|
|
|
48 Contig83_chr12_17852905_17859596 2392 chr12 17855305 ENSCAFT00000003223 ENSCAFP00000002995 E 770 Q 474925 benign N
|
|
|
49 Contig41_chr12_18725392_18725889 169 chr12 18725560 ENSCAFT00000003307 ENSCAFP00000003070 R 80 Q 609995 benign N
|
|
|
50 Contig9_chr14_26125779_26127414 486 chr14 26126264 ENSCAFT00000003515 ENSCAFP00000003259 P 123 T 482316 benign N
|
|
|
51 Contig132_chr1_101565951_101566612 255 chr1 101566210 ENSCAFT00000003560 ENSCAFP00000003298 L 588 F U unknown N
|
|
|
52 Contig142_chr1_102093954_102094392 121 chr1 102094072 ENSCAFT00000003644 ENSCAFP00000003373 K 120 E 484216 benign cfa00290=Valine, leucine and isoleucine biosynthesis.cfa00970=Aminoacyl-tRNA biosynthesis
|
|
|
53 Contig129_chr14_34071666_34074617 2313 chr14 34073957 ENSCAFT00000003824 ENSCAFP00000003537 T 282 I 475249 probably damaging N
|
|
|
54 Contig147_chr14_34262125_34262938 340 chr14 34262468 ENSCAFT00000003840 ENSCAFP00000003553 I 70 V 482333 benign N
|
|
|
55 Contig52_chr12_36031985_36035244 1237 chr12 36033208 ENSCAFT00000004092 ENSCAFP00000003784 Y 564 H 474960 benign N
|
|
|
56 Contig176_chr1_105494865_105495258 119 chr1 105494995 ENSCAFT00000004103 ENSCAFP00000003793 A 406 V 484298 benign N
|
|
|
57 Contig60_chr11_63130652_63131816 702 chr11 63131349 ENSCAFT00000004208 ENSCAFP00000003892 V 260 I 481637 benign N
|
|
|
58 Contig9_chr10_53579958_53582510 688 chr10 53580646 ENSCAFT00000004253 ENSCAFP00000003937 S 191 G 100534006.100534007.474588 benign N
|
|
|
59 Contig93_chr14_38451661_38452163 221 chr14 38451882 ENSCAFT00000004311 ENSCAFP00000003990 A 420 V 482346 benign N
|
|
|
60 Contig70_chr12_42859511_42860010 180 chr12 42859693 ENSCAFT00000004464 ENSCAFP00000004126 P 7 S 481892 possibly damaging N
|
|
|
61 Contig28_chr12_43447144_43449156 1136 chr12 43448279 ENSCAFT00000004511 ENSCAFP00000004169 V 582 M 481893 benign N
|
|
|
62 Contig18_chr13_62535238_62535697 227 chr13 62535471 ENSCAFT00000004609 ENSCAFP00000004263 E 277 D 611755 benign N
|
|
|
63 Contig282_chr1_108960925_108962235 205 chr1 108961141 ENSCAFT00000004673 ENSCAFP00000004325 A 149 V 611817 benign N
|
|
|
64 Contig110_chr1_109196028_109197290 987 chr1 109197021 ENSCAFT00000004726 ENSCAFP00000004374 E 330 D 610047 benign cfa00230=Purine metabolism.cfa00240=Pyrimidine metabolism.cfa01100=Metabolic pathways.cfa03030=DNA replication.cfa03410=Base excision repair.cfa03420=Nucleotide excision repair.cfa03430=Mismatch repair.cfa03440=Homologous recombination.cfa05166=HTLV-I infection
|
|
|
65 Contig89_chr11_69097905_69099099 568 chr11 69098443 ENSCAFT00000004799 ENSCAFP00000004445 E 1317 G U benign N
|
|
|
66 Contig118_chr14_46155051_46155557 173 chr14 46155218 ENSCAFT00000004933 ENSCAFP00000004572 S 110 L 482382 benign cfa04621=NOD-like receptor signaling pathway.cfa05133=Pertussis
|
|
|
67 Contig54_chr12_51910786_51912716 682 chr12 51911460 ENSCAFT00000004993 ENSCAFP00000004630 H 2889 Y 474995 benign cfa03008=Ribosome biogenesis in eukaryotes
|
|
|
68 Contig95_chr10_67698730_67699605 267 chr10 67698997 ENSCAFT00000005126 ENSCAFP00000004751 P 45 L U benign N
|
|
|
69 Contig265_chr17_3177908_3178389 332 chr17 3178241 ENSCAFT00000005142 ENSCAFP00000004763 A 306 P 606804 benign N
|
|
|
70 Contig322_chr17_4977962_4979371 1122 chr17 4979079 ENSCAFT00000005225 ENSCAFP00000004836 T 319 I 475647 possibly damaging N
|
|
|
71 Contig48_chr11_71453437_71456331 1725 chr11 71455160 ENSCAFT00000005323 ENSCAFP00000004927 A 226 V U benign N
|
|
|
72 Contig51_chr16_4789440_4790118 484 chr16 4789915 ENSCAFT00000005467 ENSCAFP00000005065 Q 318 H U benign N
|
|
|
73 Contig32_chr12_57224809_57225619 146 chr12 57224960 ENSCAFT00000005496 ENSCAFP00000005093 A 273 T 481925 benign N
|
|
|
74 Contig6_chr14_59310933_59312532 615 chr14 59311551 ENSCAFT00000005518 ENSCAFP00000005112 Y 304 H 492302 probably damaging cfa02010=ABC transporters.cfa04971=Gastric acid secretion.cfa04972=Pancreatic secretion.cfa04976=Bile secretion
|
|
|
75 Contig89_chr11_74391566_74395656 2856 chr11 74394408 ENSCAFT00000005653 ENSCAFP00000031395 R 450 H 403417 benign cfa04145=Phagosome.cfa04620=Toll-like receptor signaling pathway.cfa05132=Salmonella infection.cfa05133=Pertussis.cfa05134=Legionellosis.cfa05140=Leishmaniasis.cfa05142=Chagas disease (American trypanosomiasis).cfa05144=Malaria.cfa05145=Toxoplasmosis.cfa05146=Amoebiasis.cfa05152=Tuberculosis.cfa05162=Measles.cfa05164=Influenza A.cfa05323=Rheumatoid arthritis
|
|
|
76 Contig15_chr1_109713951_109714808 645 chr1 109714594 ENSCAFT00000005746 ENSCAFP00000005319 R 783 K 476410 benign cfa00071=Fatty acid metabolism.cfa03320=PPAR signaling pathway.cfa04920=Adipocytokine signaling pathway
|
|
|
77 Contig47_chr17_11258085_11259619 360 chr17 11258455 ENSCAFT00000005749 ENSCAFP00000005322 V 778 L 610007 benign N
|
|
|
78 Contig1_chr19_4352123_4352541 311 chr19 4352427 ENSCAFT00000005832 ENSCAFP00000005401 H 7 Y 403584 benign cfa04060=Cytokine-cytokine receptor interaction.cfa04630=Jak-STAT signaling pathway.cfa04672=Intestinal immune network for IgA production.cfa05166=HTLV-I infection.cfa05168=Herpes simplex infection.cfa05323=Rheumatoid arthritis
|
|
|
79 Contig57_chr12_66915864_66916357 337 chr12 66916199 ENSCAFT00000005972 ENSCAFP00000005534 F 1242 L 475012 benign N
|
|
|
80 Contig36_chr17_16182220_16182772 282 chr17 16182494 ENSCAFT00000006025 ENSCAFP00000005583 V 13 I 482980 possibly damaging N
|
|
|
81 Contig64_chr19_15052202_15053292 240 chr19 15052443 ENSCAFT00000006114 ENSCAFP00000005658 I 175 V 483829 benign N
|
|
|
82 Contig169_chr12_69415779_69417261 1136 chr12 69416908 ENSCAFT00000006157 ENSCAFP00000005701 D 85 N 475021 possibly damaging N
|
|
|
83 Contig200_chr18_15803806_15804082 169 chr18 15803976 ENSCAFT00000006219 ENSCAFP00000005760 A 66 V 483261 benign cfa04972=Pancreatic secretion.cfa04978=Mineral absorption
|
|
|
84 Contig6_chr18_15814044_15814404 97 chr18 15814150 ENSCAFT00000006219 ENSCAFP00000005760 A 413 S 483261 benign cfa04972=Pancreatic secretion.cfa04978=Mineral absorption
|
|
|
85 Contig104_chr1_110433641_110434230 183 chr1 110433810 ENSCAFT00000006272 ENSCAFP00000005811 A 315 T 484394 benign cfa00280=Valine, leucine and isoleucine degradation.cfa00290=Valine, leucine and isoleucine biosynthesis.cfa00770=Pantothenate and CoA biosynthesis.cfa01100=Metabolic pathways
|
|
|
86 Contig52_chr18_17851226_17851871 284 chr18 17851509 ENSCAFT00000006453 ENSCAFP00000005976 T 311 M 475893 probably damaging N
|
|
|
87 Contig63_chr16_12167721_12168304 388 chr16 12168099 ENSCAFT00000006479 ENSCAFP00000006000 M 634 V U benign N
|
|
|
88 Contig101_chr20_4702659_4703738 441 chr20 4703092 ENSCAFT00000006507 ENSCAFP00000006027 G 635 D 484622 probably damaging cfa03030=DNA replication.cfa04110=Cell cycle
|
|
|
89 Contig53_chr19_21456428_21457881 408 chr19 21456840 ENSCAFT00000006669 ENSCAFP00000006174 R 247 L 476094 possibly damaging N
|
|
|
90 Contig58_chr18_19883250_19884312 250 chr18 19883498 ENSCAFT00000006689 ENSCAFP00000006194 * 503 Y 475897 benign N
|
|
|
91 Contig122_chr15_17034758_17035049 142 chr15 17034893 ENSCAFT00000006827 ENSCAFP00000006320 R 117 P U benign N
|
|
|
92 Contig131_chr18_20356930_20357227 113 chr18 20357041 ENSCAFT00000006891 ENSCAFP00000006378 V 55 L 610021 benign N
|
|
|
93 Contig117_chr22_5859195_5860740 654 chr22 5859850 ENSCAFT00000007130 ENSCAFP00000006603 S 139 N 485445 benign cfa04020=Calcium signaling pathway.cfa04080=Neuroactive ligand-receptor interaction
|
|
|
94 Contig91_chr17_23506302_23507213 322 chr17 23506624 ENSCAFT00000007145 ENSCAFP00000006614 V 1644 I 607961 benign N
|
|
|
95 Contig3_chr21_16586556_16586852 105 chr21 16586661 ENSCAFT00000007244 ENSCAFP00000006709 C 33 Y 476781 possibly damaging N
|
|
|
96 Contig62_chr2_22645987_22646907 357 chr2 22646352 ENSCAFT00000007375 ENSCAFP00000006833 V 657 F 403767 probably damaging cfa04977=Vitamin digestion and absorption
|
|
|
97 Contig52_chr15_18032498_18034281 880 chr15 18033373 ENSCAFT00000007440 ENSCAFP00000006895 P 227 A 482516 benign N
|
|
|
98 Contig131_chr23_6679385_6679850 198 chr23 6679592 ENSCAFT00000007467 ENSCAFP00000006915 R 136 G 485576 possibly damaging N
|
|
|
99 Contig157_chr22_10584088_10586765 232 chr22 10584326 ENSCAFT00000007484 ENSCAFP00000006926 M 610 T 609336 benign N
|
|
|
100 Contig164_chr2_24336024_24340161 2420 chr2 24338436 ENSCAFT00000007527 ENSCAFP00000006969 S 824 C 607108 probably damaging N
|
|
|
101 Contig109_chr2_24557417_24558710 808 chr2 24558229 ENSCAFT00000007553 ENSCAFP00000006994 L 606 V 487123 benign cfa03450=Non-homologous end-joining.cfa05340=Primary immunodeficiency
|
|
|
102 Contig194_chr15_18573761_18574204 142 chr15 18573904 ENSCAFT00000007697 ENSCAFP00000007130 V 381 I 475382 benign N
|
|
|
103 Contig133_chr23_9924894_9925887 125 chr23 9925016 ENSCAFT00000007703 ENSCAFP00000007136 P 355 S 477019 benign cfa03430=Mismatch repair.cfa03460=Fanconi anemia pathway.cfa05200=Pathways in cancer.cfa05210=Colorectal cancer.cfa05213=Endometrial cancer
|
|
|
104 Contig31_chr23_10199273_10203629 4073 chr23 10203350 ENSCAFT00000007747 ENSCAFP00000007179 A 1844 V U benign N
|
|
|
105 Contig21_chr23_10308212_10309269 513 chr23 10308732 ENSCAFT00000007774 ENSCAFP00000007206 K 72 R 477021 benign cfa04510=Focal adhesion.cfa04512=ECM-receptor interaction.cfa04514=Cell adhesion molecules (CAMs).cfa04810=Regulation of actin cytoskeleton.cfa05410=Hypertrophic cardiomyopathy (HCM).cfa05412=Arrhythmogenic right ventricular cardiomyopathy (ARVC).cfa05414=Dilated cardiomyopathy
|
|
|
106 Contig211_chr1_114924893_114925515 171 chr1 114925067 ENSCAFT00000007776 ENSCAFP00000007208 P 1988 A U benign N
|
|
|
107 Contig35_chr2_27160577_27161526 804 chr2 27161367 ENSCAFT00000007779 ENSCAFP00000007211 G 473 R 478007.478008 probably damaging cfa03060=Protein export.cfa04141=Protein processing in endoplasmic reticulum.cfa04145=Phagosome
|
|
|
108 Contig79_chr17_24285444_24286769 1263 chr17 24286694 ENSCAFT00000007859 ENSCAFP00000007285 S 209 T 483010 benign N
|
|
|
109 Contig74_chr23_10871047_10871362 70 chr23 10871116 ENSCAFT00000007951 ENSCAFP00000007365 I 474 V U benign N
|
|
|
110 Contig34_chr16_18928689_18932806 3409 chr16 18932072 ENSCAFT00000007959 ENSCAFP00000007370 A 3754 S 482810.611087 benign cfa00310=Lysine degradation
|
|
|
111 Contig52_chr21_24452521_24454405 725 chr21 24453245 ENSCAFT00000008012 ENSCAFP00000007418 M 289 T 485173 possibly damaging N
|
|
|
112 Contig261_chr1_115563599_115564561 560 chr1 115564156 ENSCAFT00000008063 ENSCAFP00000007465 A 63 T 484489 possibly damaging N
|
|
|
113 Contig62_chr19_41037398_41039465 159 chr19 41037564 ENSCAFT00000008142 ENSCAFP00000007541 C 744 Y 476128 possibly damaging N
|
|
|
114 Contig84_chr1_115960693_115962811 1467 chr1 115962120 ENSCAFT00000008198 ENSCAFP00000007593 W 61 R 612489 benign N
|
|
|
115 Contig135_chr23_14160194_14160717 270 chr23 14160468 ENSCAFT00000008413 ENSCAFP00000007796 V 298 I U benign N
|
|
|
116 Contig41_chr17_26203621_26205196 1407 chr17 26205028 ENSCAFT00000008540 ENSCAFP00000007913 H 172 R 483021 benign N
|
|
|
117 Contig260_chr1_116076701_116078120 746 chr1 116077446 ENSCAFT00000008586 ENSCAFP00000007956 T 2486 I 484499 benign N
|
|
|
118 Contig19_chr23_14811332_14815323 1987 chr23 14813327 ENSCAFT00000008588 ENSCAFP00000007958 S 690 L U unknown N
|
|
|
119 Contig180_chr2_35061773_35062172 166 chr2 35061941 ENSCAFT00000008673 ENSCAFP00000008039 T 920 M 478018 probably damaging N
|
|
|
120 Contig106_chr21_26153874_26154496 107 chr21 26153984 ENSCAFT00000008678 ENSCAFP00000008044 A 458 T 485188 benign N
|
|
|
121 Contig3_chr19_45625337_45630123 2563 chr19 45627887 ENSCAFT00000008728 ENSCAFP00000008094 V 1264 I U benign N
|
|
|
122 Contig51_chr22_48760401_48761638 636 chr22 48761047 ENSCAFT00000008769 ENSCAFP00000008132 R 1071 K 485523 benign cfa02010=ABC transporters.cfa04976=Bile secretion
|
|
|
123 Contig10_chr15_21173640_21174011 212 chr15 21173839 ENSCAFT00000008831 ENSCAFP00000008192 V 191 I 475398 benign N
|
|
|
124 Contig6_chr24_14680423_14681438 782 chr24 14681208 ENSCAFT00000009074 ENSCAFP00000008417 H 562 R 485769 possibly damaging cfa04330=Notch signaling pathway
|
|
|
125 Contig60_chr9_4528464_4529207 262 chr9 4528727 ENSCAFT00000009114 ENSCAFP00000008453 C 24 F 483354 possibly damaging N
|
|
|
126 Contig54_chr15_29510545_29512205 400 chr15 29510955 ENSCAFT00000009614 ENSCAFP00000008928 H 190 R 475416 benign N
|
|
|
127 Contig46_chr25_5067588_5068089 39 chr25 5067627 ENSCAFT00000009698 ENSCAFP00000009003 S 17 N 486001 benign N
|
|
|
128 Contig126_chr25_5114359_5115799 643 chr25 5114996 ENSCAFT00000009710 ENSCAFP00000009013 R 1952 C 486002 possibly damaging N
|
|
|
129 Contig41_chr26_3455305_3455893 329 chr26 3455620 ENSCAFT00000010094 ENSCAFP00000009363 S 909 A 486223 benign cfa00230=Purine metabolism.cfa00240=Pyrimidine metabolism.cfa01100=Metabolic pathways.cfa03030=DNA replication.cfa03410=Base excision repair.cfa03420=Nucleotide excision repair.cfa05166=HTLV-I infection
|
|
|
130 Contig55_chr26_3463883_3465235 1074 chr26 3464998 ENSCAFT00000010094 ENSCAFP00000009363 R 1273 S 486223 benign cfa00230=Purine metabolism.cfa00240=Pyrimidine metabolism.cfa01100=Metabolic pathways.cfa03030=DNA replication.cfa03410=Base excision repair.cfa03420=Nucleotide excision repair.cfa05166=HTLV-I infection
|
|
|
131 Contig63_chr26_3467460_3468420 195 chr26 3467661 ENSCAFT00000010094 ENSCAFP00000009363 E 1542 Q 486223 benign cfa00230=Purine metabolism.cfa00240=Pyrimidine metabolism.cfa01100=Metabolic pathways.cfa03030=DNA replication.cfa03410=Base excision repair.cfa03420=Nucleotide excision repair.cfa05166=HTLV-I infection
|
|
|
132 Contig13_chr16_32259141_32259752 344 chr16 32259472 ENSCAFT00000010141 ENSCAFP00000009407 I 326 T 482857 benign cfa04360=Axon guidance
|
|
|
133 Contig59_chr21_32994329_32995926 1195 chr21 32995538 ENSCAFT00000010439 ENSCAFP00000009680 H 230 R 610992 benign N
|
|
|
134 Contig39_chr20_24938452_24941620 1292 chr20 24939734 ENSCAFT00000010496 ENSCAFP00000009730 S 28 P 415126 benign cfa04380=Osteoclast differentiation.cfa04916=Melanogenesis.cfa05200=Pathways in cancer.cfa05218=Melanoma
|
|
|
135 Contig2_chr18_28546360_28546760 277 chr18 28546640 ENSCAFT00000010516 ENSCAFP00000009748 P 471 S U benign N
|
|
|
136 Contig23_chr20_25560598_25562858 928 chr20 25561520 ENSCAFT00000010531 ENSCAFP00000009762 T 749 I 484693 benign N
|
|
|
137 Contig209_chr18_28672330_28672791 376 chr18 28672689 ENSCAFT00000010559 ENSCAFP00000009790 A 33 D 483405 unknown N
|
|
|
138 Contig261_chr18_28694652_28696968 1808 chr18 28696427 ENSCAFT00000010559 ENSCAFP00000009790 P 1443 L 483405 possibly damaging N
|
|
|
139 Contig30_chr25_12008255_12009009 151 chr25 12008417 ENSCAFT00000010593 ENSCAFP00000009822 Q 151 H U benign N
|
|
|
140 Contig46_chr29_3065854_3067420 1265 chr29 3067078 ENSCAFT00000010616 ENSCAFP00000009842 V 3253 A 474176 benign cfa03450=Non-homologous end-joining.cfa04110=Cell cycle
|
|
|
141 Contig59_chr28_3755477_3757019 935 chr28 3756419 ENSCAFT00000010630 ENSCAFP00000009853 R 923 Q 486770 possibly damaging N
|
|
|
142 Contig90_chr29_6393993_6395503 951 chr29 6394948 ENSCAFT00000010829 ENSCAFP00000010033 Y 257 C 486944 benign N
|
|
|
143 Contig42_chr16_39015800_39016389 319 chr16 39016119 ENSCAFT00000010865 ENSCAFP00000010068 D 71 N U possibly damaging N
|
|
|
144 Contig95_chr21_34533214_34535079 1133 chr21 34534321 ENSCAFT00000010931 ENSCAFP00000010131 E 118 G 485368 benign N
|
|
|
145 Contig82_chr21_34524815_34525170 247 chr21 34525072 ENSCAFT00000010931 ENSCAFP00000010131 Q 499 R 485368 benign N
|
|
|
146 Contig32_chr24_22727492_22727986 147 chr24 22727648 ENSCAFT00000010977 ENSCAFP00000010173 P 278 L U possibly damaging N
|
|
|
147 Contig45_chr16_42405571_42406148 269 chr16 42405837 ENSCAFT00000010988 ENSCAFP00000010184 H 406 R 482891 benign cfa04145=Phagosome
|
|
|
148 Contig66_chr15_43321121_43321872 642 chr15 43321764 ENSCAFT00000011187 ENSCAFP00000010364 F 543 L 475441 benign N
|
|
|
149 Contig184_chr27_5103641_5104991 275 chr27 5103979 ENSCAFT00000011380 ENSCAFP00000010541 V 864 A U benign N
|
|
|
150 Contig88_chr17_39320200_39320765 204 chr17 39320404 ENSCAFT00000011397 ENSCAFP00000010558 S 1911 N 475750 benign cfa04110=Cell cycle.cfa04114=Oocyte meiosis.cfa04120=Ubiquitin mediated proteolysis.cfa04914=Progesterone-mediated oocyte maturation.cfa05166=HTLV-I infection
|
|
|
151 Contig8_chr16_47195242_47195504 193 chr16 47195429 ENSCAFT00000011721 ENSCAFP00000010862 S 4369 W 475621 benign N
|
|
|
152 Contig84_chr27_5882441_5882771 145 chr27 5882579 ENSCAFT00000011730 ENSCAFP00000010871 C 289 S 486534 benign N
|
|
|
153 Contig42_chr24_25316755_25317362 320 chr24 25317091 ENSCAFT00000011771 ENSCAFP00000010910 G 22 S 477193 benign N
|
|
|
154 Contig45_chr24_25318544_25319490 734 chr24 25319299 ENSCAFT00000011771 ENSCAFP00000010910 V 187 A 477193 benign N
|
|
|
155 Contig31_chr24_25434125_25435133 853 chr24 25434975 ENSCAFT00000011789 ENSCAFP00000010928 S 91 I 609978 benign N
|
|
|
156 Contig20_chr3_10579133_10580085 600 chr3 10579729 ENSCAFT00000011968 ENSCAFP00000011099 K 165 E 488881 benign cfa00760=Nicotinate and nicotinamide metabolism.cfa04146=Peroxisome
|
|
|
157 Contig45_chr2_54585564_54588038 1047 chr2 54586611 ENSCAFT00000012081 ENSCAFP00000011198 T 969 M 478082 benign cfa04621=NOD-like receptor signaling pathway
|
|
|
158 Contig156_chr1_122375741_122376035 168 chr1 122375904 ENSCAFT00000012133 ENSCAFP00000011248 R 628 K 611998 benign N
|
|
|
159 Contig153_chr1_124036982_124040108 1588 chr1 124038585 ENSCAFT00000012159 ENSCAFP00000011272 A 887 T 484609 benign N
|
|
|
160 Contig32_chr24_26900375_26900913 394 chr24 26900761 ENSCAFT00000012254 ENSCAFP00000011358 H 51 Y U benign N
|
|
|
161 Contig103_chr16_48829082_48829675 123 chr16 48829205 ENSCAFT00000012381 ENSCAFP00000011471 E 369 G 475632 possibly damaging N
|
|
|
162 Contig25_chr18_41490135_41493501 534 chr18 41490665 ENSCAFT00000012414 ENSCAFP00000011503 R 703 C 483489 probably damaging cfa04520=Adherens junction.cfa04670=Leukocyte transendothelial migration
|
|
|
163 Contig69_chr16_49314879_49317228 1810 chr16 49316689 ENSCAFT00000012456 ENSCAFP00000011541 P 431 L 475636 probably damaging cfa00565=Ether lipid metabolism
|
|
|
164 Contig71_chr17_42734055_42736474 2240 chr17 42736298 ENSCAFT00000012478 ENSCAFP00000011561 R 307 Q 483083 benign cfa00830=Retinol metabolism
|
|
|
165 Contig17_chr17_43378842_43379885 305 chr17 43379148 ENSCAFT00000012676 ENSCAFP00000011740 T 196 M U probably damaging N
|
|
|
166 Contig195_chr27_7047911_7049009 555 chr27 7048468 ENSCAFT00000012942 ENSCAFP00000011978 R 881 L 477608 benign N
|
|
|
167 Contig112_chr30_4254316_4256576 1478 chr30 4255785 ENSCAFT00000012974 ENSCAFP00000012007 V 2939 I U benign N
|
|
|
168 Contig43_chr20_39124486_39124798 114 chr20 39124607 ENSCAFT00000013097 ENSCAFP00000012118 G 325 R 607274 possibly damaging N
|
|
|
169 Contig96_chr16_55849292_55849592 194 chr16 55849494 ENSCAFT00000013360 ENSCAFP00000012363 A 41 S 482932 benign cfa04060=Cytokine-cytokine receptor interaction.cfa04150=mTOR signaling pathway.cfa04510=Focal adhesion.cfa05200=Pathways in cancer.cfa05211=Renal cell carcinoma.cfa05212=Pancreatic cancer.cfa05219=Bladder cancer
|
|
|
170 Contig91_chr17_51684551_51689453 4154 chr17 51688687 ENSCAFT00000013395 ENSCAFP00000012395 P 306 L 475784 benign N
|
|
|
171 Contig192_chr26_12794366_12794712 143 chr26 12794506 ENSCAFT00000014076 ENSCAFP00000013021 V 2478 I 477486 benign N
|
|
|
172 Contig191_chr31_30109152_30109760 212 chr31 30109363 ENSCAFT00000014113 ENSCAFP00000013055 A 1813 T 487735 probably damaging N
|
|
|
173 Contig116_chr24_29683980_29684819 101 chr24 29684079 ENSCAFT00000014115 ENSCAFP00000013057 R 836 C 485868 probably damaging N
|
|
|
174 Contig8_chr32_9413601_9414435 74 chr32 9413675 ENSCAFT00000014257 ENSCAFP00000013183 N 236 K 478452 probably damaging cfa00270=Cysteine and methionine metabolism
|
|
|
175 Contig90_chr21_43253791_43254774 189 chr21 43253974 ENSCAFT00000014325 ENSCAFP00000013248 I 758 V U benign N
|
|
|
176 Contig76_chr24_30292767_30294101 552 chr24 30293321 ENSCAFT00000014346 ENSCAFP00000013267 A 349 T U benign N
|
|
|
177 Contig21_chr25_37121451_37122072 177 chr25 37121616 ENSCAFT00000014616 ENSCAFP00000013518 V 157 L 486118 benign N
|
|
|
178 Contig15_chr36_6357141_6362626 5226 chr36 6362346 ENSCAFT00000014702 ENSCAFP00000013598 N 138 K 607626 possibly damaging N
|
|
|
179 Contig64_chr17_54734453_54734993 109 chr17 54734552 ENSCAFT00000014707 ENSCAFP00000013603 S 302 L 483124 benign N
|
|
|
180 Contig91_chr18_46134014_46136042 330 chr18 46134347 ENSCAFT00000014736 ENSCAFP00000013630 A 214 S 483635 benign cfa00561=Glycerolipid metabolism.cfa00564=Glycerophospholipid metabolism.cfa01100=Metabolic pathways.cfa04070=Phosphatidylinositol signaling system
|
|
|
181 Contig111_chr31_31237314_31238628 920 chr31 31238220 ENSCAFT00000014822 ENSCAFP00000013714 S 143 C 478408 benign N
|
|
|
182 Contig77_chr38_3502296_3503058 349 chr38 3502639 ENSCAFT00000015260 ENSCAFP00000014122 K 666 E 478932 benign N
|
|
|
183 Contig59_chr38_3998294_3999004 369 chr38 3998672 ENSCAFT00000015347 ENSCAFP00000014201 V 791 I U benign N
|
|
|
184 Contig123_chr31_34367825_34368648 664 chr31 34368468 ENSCAFT00000015534 ENSCAFP00000014373 H 204 Q U possibly damaging N
|
|
|
185 Contig43_chr30_11874641_11875130 198 chr30 11874850 ENSCAFT00000015654 ENSCAFP00000014488 R 3422 C U benign N
|
|
|
186 Contig9_chr20_40741488_40743247 1027 chr20 40742525 ENSCAFT00000015816 ENSCAFP00000014638 M 183 V 484744 benign N
|
|
|
187 Contig137_chr5_7048977_7051042 863 chr5 7049840 ENSCAFT00000015844 ENSCAFP00000014662 A 311 V 479391 benign N
|
|
|
188 Contig9_chr28_17675067_17680985 1564 chr28 17676618 ENSCAFT00000015971 ENSCAFP00000014772 R 515 P 477805 unknown N
|
|
|
189 Contig126_chr30_12286682_12287475 407 chr30 12287101 ENSCAFT00000016062 ENSCAFP00000014854 V 450 I 487517 benign cfa00052=Galactose metabolism.cfa00500=Starch and sucrose metabolism.cfa01100=Metabolic pathways
|
|
|
190 Contig127_chr30_12287497_12288447 608 chr30 12288095 ENSCAFT00000016062 ENSCAFP00000014854 T 495 M 487517 benign cfa00052=Galactose metabolism.cfa00500=Starch and sucrose metabolism.cfa01100=Metabolic pathways
|
|
|
191 Contig13_chr38_5058391_5058630 66 chr38 5058458 ENSCAFT00000016099 ENSCAFP00000014887 F 412 L 478943 benign N
|
|
|
192 Contig169_chr35_19985467_19986000 455 chr35 19985921 ENSCAFT00000016165 ENSCAFP00000014950 T 175 I 478733 benign N
|
|
|
193 Contig2_chr35_21794536_21795092 291 chr35 21794865 ENSCAFT00000016208 ENSCAFP00000014992 V 84 A 488238 benign cfa00561=Glycerolipid metabolism.cfa00564=Glycerophospholipid metabolism.cfa01100=Metabolic pathways
|
|
|
194 Contig141_chr26_19278751_19279229 364 chr26 19279128 ENSCAFT00000016284 ENSCAFP00000015064 N 29 S 404011 benign cfa00564=Glycerophospholipid metabolism.cfa00565=Ether lipid metabolism.cfa00590=Arachidonic acid metabolism.cfa00591=Linoleic acid metabolism.cfa00592=alpha-Linolenic acid metabolism.cfa01100=Metabolic pathways.cfa04010=MAPK signaling pathway.cfa04270=Vascular smooth muscle contraction.cfa04370=VEGF signaling pathway.cfa04664=Fc epsilon RI signaling pathway.cfa04724=Glutamatergic synapse.cfa04730=Long-term depression.cfa04912=GnRH signaling pathway.cfa04972=Pancreatic secretion.cfa04975=Fat digestion and absorption.cfa05145=Toxoplasmosis
|
|
|
195 Contig179_chr3_40781459_40782026 285 chr3 40781763 ENSCAFT00000016410 ENSCAFP00000015182 D 1174 N 488699 benign N
|
|
|
196 Contig237_chr21_53631024_53632458 203 chr21 53631227 ENSCAFT00000016459 ENSCAFP00000015227 C 47 W 403799 probably damaging cfa04664=Fc epsilon RI signaling pathway.cfa05310=Asthma
|
|
|
197 Contig186_chr2_71203100_71204111 202 chr2 71203303 ENSCAFT00000016485 ENSCAFP00000015250 S 188 T 478144 benign cfa00330=Arginine and proline metabolism.cfa01100=Metabolic pathways
|
|
|
198 Contig1_chr28_18779291_18780149 325 chr28 18779619 ENSCAFT00000016578 ENSCAFP00000015340 N 245 Y U probably damaging N
|
|
|
199 Contig166_chr4_77425871_77426835 797 chr4 77426667 ENSCAFT00000016670 ENSCAFP00000015429 D 115 G 479370 benign cfa00970=Aminoacyl-tRNA biosynthesis
|
|
|
200 Contig35_chr24_36806524_36807086 367 chr24 36806891 ENSCAFT00000016727 ENSCAFP00000015478 F 345 L 485910 benign N
|
|
|
201 Contig45_chr37_8610877_8611425 194 chr37 8611078 ENSCAFT00000016761 ENSCAFP00000015511 D 2849 N 488452 possibly damaging N
|
|
|
202 Contig39_chr28_19446540_19447838 1068 chr28 19447566 ENSCAFT00000016791 ENSCAFP00000015537 A 1596 E U benign N
|
|
|
203 Contig161_chr18_51013230_51015381 1494 chr18 51014735 ENSCAFT00000016827 ENSCAFP00000015571 L 977 V 475999 benign N
|
|
|
204 Contig25_chr28_19619108_19621267 1728 chr28 19620832 ENSCAFT00000016848 ENSCAFP00000034237 I 108 V 609723 benign N
|
|
|
205 Contig33_chr20_42063173_42064259 623 chr20 42063789 ENSCAFT00000017070 ENSCAFP00000015794 V 179 M U probably damaging N
|
|
|
206 Contig39_chr38_14681397_14682234 384 chr38 14681781 ENSCAFT00000017072 ENSCAFP00000015796 H 282 N 488593 unknown N
|
|
|
207 Contig6_chr32_27303975_27304541 425 chr32 27304407 ENSCAFT00000017178 ENSCAFP00000015896 S 354 T 610098 benign N
|
|
|
208 Contig173_chr38_17709765_17711029 179 chr38 17709941 ENSCAFT00000017240 ENSCAFP00000015955 G 464 R U benign N
|
|
|
209 Contig52_chr32_27452924_27453332 91 chr32 27452999 ENSCAFT00000017249 ENSCAFP00000015964 A 22 S U benign N
|
|
|
210 Contig319_chr34_14684259_14684663 353 chr34 14684613 ENSCAFT00000017314 ENSCAFP00000016025 R 5 Q 478632 benign N
|
|
|
211 Contig32_chr2_72269353_72269814 349 chr2 72269708 ENSCAFT00000017327 ENSCAFP00000016037 P 853 L 487317 possibly damaging N
|
|
|
212 Contig206_chr9_18720001_18720613 155 chr9 18720160 ENSCAFT00000017373 ENSCAFP00000016082 D 1621 E 480456 benign cfa02010=ABC transporters
|
|
|
213 Contig35_chr37_10562149_10562621 74 chr37 10562222 ENSCAFT00000017444 ENSCAFP00000016153 I 975 V 478858 benign cfa04727=GABAergic synapse
|
|
|
214 Contig1_chr30_12655575_12656916 370 chr30 12655947 ENSCAFT00000017777 ENSCAFP00000016457 L 639 M 608886 probably damaging N
|
|
|
215 Contig63_chr27_23738716_23739879 1131 chr27 23739850 ENSCAFT00000017892 ENSCAFP00000016566 P 642 L 486627 benign N
|
|
|
216 Contig44_chr28_28123120_28124627 1348 chr28 28124495 ENSCAFT00000017967 ENSCAFP00000016639 V 261 A 477827 benign N
|
|
|
217 Contig23_chrX_6416128_6417014 455 chrX 6416585 ENSCAFT00000018017 ENSCAFP00000016684 H 111 R 491733 possibly damaging N
|
|
|
218 Contig31_chr7_8282189_8286932 3631 chr7 8285875 ENSCAFT00000018057 ENSCAFP00000016724 L 655 P 490260 benign N
|
|
|
219 Contig318_chr6_8706066_8706350 76 chr6 8706142 ENSCAFT00000018106 ENSCAFP00000016769 K 318 N 607700 possibly damaging cfa04062=Chemokine signaling pathway.cfa04145=Phagosome.cfa04380=Osteoclast differentiation.cfa04666=Fc gamma R-mediated phagocytosis.cfa04670=Leukocyte transendothelial migration.cfa05140=Leishmaniasis
|
|
|
220 Contig36_chr32_33046881_33048369 1118 chr32 33047990 ENSCAFT00000018307 ENSCAFP00000016954 E 555 A 403657 benign cfa04010=MAPK signaling pathway.cfa04012=ErbB signaling pathway.cfa04060=Cytokine-cytokine receptor interaction.cfa04144=Endocytosis.cfa04510=Focal adhesion.cfa04540=Gap junction.cfa04810=Regulation of actin cytoskeleton.cfa05160=Hepatitis C.cfa05200=Pathways in cancer.cfa05212=Pancreatic cancer.cfa05213=Endometrial cancer.cfa05214=Glioma.cfa05215=Prostate cancer.cfa05218=Melanoma.cfa05219=Bladder cancer.cfa05223=Non-small cell lung cancer
|
|
|
221 Contig32_chr5_14476595_14477214 347 chr5 14476948 ENSCAFT00000018571 ENSCAFP00000017201 V 209 A 610296 benign N
|
|
|
222 Contig88_chr34_19031138_19031937 343 chr34 19031477 ENSCAFT00000018684 ENSCAFP00000017309 K 670 R 478645 benign cfa00280=Valine, leucine and isoleucine degradation.cfa01100=Metabolic pathways
|
|
|
223 Contig188_chr25_47927372_47928085 557 chr25 47927941 ENSCAFT00000018758 ENSCAFP00000017379 K 228 R 486167 benign cfa00561=Glycerolipid metabolism.cfa00564=Glycerophospholipid metabolism.cfa01100=Metabolic pathways.cfa04070=Phosphatidylinositol signaling system
|
|
|
224 Contig36_chr37_12924359_12924740 86 chr37 12924449 ENSCAFT00000018786 ENSCAFP00000017406 D 187 Y 608849 probably damaging cfa00280=Valine, leucine and isoleucine degradation.cfa00350=Tyrosine metabolism.cfa00380=Tryptophan metabolism.cfa00750=Vitamin B6 metabolism.cfa00760=Nicotinate and nicotinamide metabolism.cfa00982=Drug metabolism - cytochrome P450.cfa01100=Metabolic pathways
|
|
|
225 Contig3_chr34_19471626_19472377 337 chr34 19471956 ENSCAFT00000018788 ENSCAFP00000017408 R 239 Q 488096 possibly damaging N
|
|
|
226 Contig80_chr4_11155760_11156827 952 chr4 11156735 ENSCAFT00000018796 ENSCAFP00000017416 S 661 N 479204 benign cfa00564=Glycerophospholipid metabolism.cfa04146=Peroxisome
|
|
|
227 Contig56_chr8_7093747_7095987 683 chr8 7094428 ENSCAFT00000018813 ENSCAFP00000017431 P 126 R 490620 unknown N
|
|
|
228 Contig82_chr8_7111986_7114065 1351 chr8 7113329 ENSCAFT00000018871 ENSCAFP00000017488 R 608 H 480255 probably damaging cfa00010=Glycolysis / Gluconeogenesis.cfa00020=Citrate cycle (TCA cycle).cfa00620=Pyruvate metabolism.cfa01100=Metabolic pathways.cfa03320=PPAR signaling pathway.cfa04910=Insulin signaling pathway.cfa04920=Adipocytokine signaling pathway.cfa04964=Proximal tubule bicarbonate reclamation
|
|
|
229 Contig172_chr33_28585454_28586084 228 chr33 28585687 ENSCAFT00000018884 ENSCAFP00000017500 R 36 K 478584 benign N
|
|
|
230 Contig113_chr5_16682954_16684491 688 chr5 16683641 ENSCAFT00000018997 ENSCAFP00000017606 F 41 L 489360 benign N
|
|
|
231 Contig36_chr28_31449413_31452160 2111 chr28 31451506 ENSCAFT00000019041 ENSCAFP00000017650 P 252 H 477834 benign cfa04144=Endocytosis
|
|
|
232 Contig80_chr3_55628026_55628800 392 chr3 55628403 ENSCAFT00000019070 ENSCAFP00000017677 R 805 K 403913 benign cfa00480=Glutathione metabolism.cfa01100=Metabolic pathways.cfa04614=Renin-angiotensin system.cfa04640=Hematopoietic cell lineage
|
|
|
233 Contig99_chr7_11816365_11819255 806 chr7 11817201 ENSCAFT00000019101 ENSCAFP00000017707 C 305 G 490276 benign N
|
|
|
234 Contig114_chr4_12744102_12745318 148 chr4 12744256 ENSCAFT00000019279 ENSCAFP00000017880 I 700 V U benign N
|
|
|
235 Contig82_chr7_13056757_13058281 974 chr7 13057742 ENSCAFT00000019316 ENSCAFP00000017915 S 283 N 609933 benign cfa00564=Glycerophospholipid metabolism
|
|
|
236 Contig280_chr25_51367477_51367885 70 chr25 51367542 ENSCAFT00000019610 ENSCAFP00000018191 S 97 L U benign N
|
|
|
237 Contig35_chr20_43508791_43509352 460 chr20 43509254 ENSCAFT00000019627 ENSCAFP00000018204 V 77 A 608455 benign cfa00190=Oxidative phosphorylation.cfa01100=Metabolic pathways.cfa04260=Cardiac muscle contraction.cfa05010=Alzheimer's disease.cfa05012=Parkinson's disease.cfa05016=Huntington's disease
|
|
|
238 Contig36_chr20_43509362_43510980 1484 chr20 43510860 ENSCAFT00000019627 ENSCAFP00000018204 D 181 N 608455 benign cfa00190=Oxidative phosphorylation.cfa01100=Metabolic pathways.cfa04260=Cardiac muscle contraction.cfa05010=Alzheimer's disease.cfa05012=Parkinson's disease.cfa05016=Huntington's disease
|
|
|
239 Contig59_chr25_51807653_51809044 1064 chr25 51808739 ENSCAFT00000019760 ENSCAFP00000018330 R 235 K U benign N
|
|
|
240 Contig96_chr36_17712997_17714068 556 chr36 17713559 ENSCAFT00000019807 ENSCAFP00000018374 T 423 I 478789 benign N
|
|
|
241 Contig163_chr28_34927368_34929275 1128 chr28 34928486 ENSCAFT00000019866 ENSCAFP00000018425 A 2659 T 477850 benign N
|
|
|
242 Contig74_chr33_31230250_31230874 246 chr33 31230493 ENSCAFT00000019938 ENSCAFP00000018492 G 113 S 488016 probably damaging N
|
|
|
243 Contig130_chr7_15553315_15558308 3186 chr7 15556497 ENSCAFT00000020009 ENSCAFP00000018561 K 1513 N U benign N
|
|
|
244 Contig160_chr2_76816412_76817166 354 chr2 76816779 ENSCAFT00000020143 ENSCAFP00000018683 I 190 V 478173 benign N
|
|
|
245 Contig219_chr33_31871568_31871771 81 chr33 31871646 ENSCAFT00000020195 ENSCAFP00000018733 N 346 H U probably damaging N
|
|
|
246 Contig254_chr24_50001599_50001992 151 chr24 50001767 ENSCAFT00000020266 ENSCAFP00000018803 R 239 Q U benign N
|
|
|
247 Contig40_chr37_15283702_15285945 1908 chr37 15285621 ENSCAFT00000020408 ENSCAFP00000018937 A 809 G U unknown N
|
|
|
248 Contig59_chr20_43702094_43703358 450 chr20 43702540 ENSCAFT00000020438 ENSCAFP00000018965 S 217 A U benign N
|
|
|
249 Contig75_chr3_57465650_57466327 377 chr3 57466017 ENSCAFT00000020863 ENSCAFP00000019371 L 205 F 609716 probably damaging N
|
|
|
250 Contig155_chr2_79195879_79199423 2014 chr2 79197892 ENSCAFT00000021154 ENSCAFP00000019645 G 549 S U benign N
|
|
|
251 Contig155_chr2_79195879_79199423 3136 chr2 79199014 ENSCAFT00000021154 ENSCAFP00000019645 R 923 C U probably damaging N
|
|
|
252 Contig59_chr5_19784971_19787384 1310 chr5 19786293 ENSCAFT00000021222 ENSCAFP00000019707 V 171 I 479428.489393 benign cfa03320=PPAR signaling pathway
|
|
|
253 Contig41_chr30_14304605_14305465 206 chr30 14304816 ENSCAFT00000021612 ENSCAFP00000020069 A 157 G U benign N
|
|
|
254 Contig47_chr20_45043804_45044476 317 chr20 45044117 ENSCAFT00000021659 ENSCAFP00000020114 V 281 I 609323 benign N
|
|
|
255 Contig46_chr4_22849549_22849829 123 chr4 22849673 ENSCAFT00000021752 ENSCAFP00000020204 V 646 M U probably damaging N
|
|
|
256 Contig141_chr7_22360980_22361690 242 chr7 22361233 ENSCAFT00000021777 ENSCAFP00000020227 K 1862 R U unknown N
|
|
|
257 Contig59_chr30_14758622_14760653 1186 chr30 14759817 ENSCAFT00000021792 ENSCAFP00000020241 S 284 R 609256 benign N
|
|
|
258 Contig57_chr27_39696388_39698349 1026 chr27 39697428 ENSCAFT00000021846 ENSCAFP00000020293 Q 588 R 477699 benign cfa04610=Complement and coagulation cascades
|
|
|
259 Contig83_chr27_40151814_40153141 738 chr27 40152551 ENSCAFT00000022064 ENSCAFP00000020490 S 191 R 477702 benign N
|
|
|
260 Contig105_chr6_11901733_11904968 406 chr6 11902145 ENSCAFT00000022289 ENSCAFP00000020701 Y 55 H 479732 probably damaging cfa04621=NOD-like receptor signaling pathway
|
|
|
261 Contig43_chr36_25298890_25299602 235 chr36 25299132 ENSCAFT00000022319 ENSCAFP00000020728 E 11731 K 610299.610339 unknown N
|
|
|
262 Contig3_chr36_25193150_25202641 2802 chr36 25195983 ENSCAFT00000022319 ENSCAFP00000020728 I 30137 V 610299.610339 benign N
|
|
|
263 Contig585_chr3_61201332_61201904 139 chr3 61201468 ENSCAFT00000022529 ENSCAFP00000020918 L 97 V 479067 benign cfa00071=Fatty acid metabolism.cfa03320=PPAR signaling pathway.cfa04920=Adipocytokine signaling pathway
|
|
|
264 Contig1_chr20_46714929_46715937 434 chr20 46715327 ENSCAFT00000022571 ENSCAFP00000020958 A 18 P 484804 unknown N
|
|
|
265 Contig7_chr8_29376780_29378260 158 chr8 29376937 ENSCAFT00000022576 ENSCAFP00000020962 T 852 A 490678 benign N
|
|
|
266 Contig74_chr8_29656170_29657212 595 chr8 29656776 ENSCAFT00000022697 ENSCAFP00000021080 E 974 K 490682 possibly damaging cfa04010=MAPK signaling pathway.cfa04012=ErbB signaling pathway.cfa04062=Chemokine signaling pathway.cfa04320=Dorso-ventral axis formation.cfa04510=Focal adhesion.cfa04540=Gap junction.cfa04630=Jak-STAT signaling pathway.cfa04650=Natural killer cell mediated cytotoxicity.cfa04660=T cell receptor signaling pathway.cfa04662=B cell receptor signaling pathway.cfa04664=Fc epsilon RI signaling pathway.cfa04722=Neurotrophin signaling pathway.cfa04810=Regulation of actin cytoskeleton.cfa04910=Insulin signaling pathway.cfa04912=GnRH signaling pathway.cfa05160=Hepatitis C.cfa05200=Pathways in cancer.cfa05211=Renal cell carcinoma.cfa05213=Endometrial cancer.cfa05214=Glioma.cfa05215=Prostate cancer.cfa05220=Chronic myeloid leukemia.cfa05221=Acute myeloid leukemia.cfa05223=Non-small cell lung cancer
|
|
|
267 Contig45_chr4_25273541_25274402 608 chr4 25274121 ENSCAFT00000022760 ENSCAFP00000021140 S 30 F 479239 probably damaging cfa04360=Axon guidance
|
|
|
268 Contig96_chr37_26111249_26111450 108 chr37 26111364 ENSCAFT00000022884 ENSCAFP00000021256 K 260 R 478902 benign cfa03450=Non-homologous end-joining
|
|
|
269 Contig196_chr3_62434637_62435063 203 chr3 62434823 ENSCAFT00000022915 ENSCAFP00000021284 L 174 P 488785 benign N
|
|
|
270 Contig15_chr6_12238116_12239737 1287 chr6 12239420 ENSCAFT00000022961 ENSCAFP00000021328 E 165 K 479735 benign N
|
|
|
271 Contig175_chr5_27267391_27267870 57 chr5 27267451 ENSCAFT00000023032 ENSCAFP00000021395 N 1094 S 479450 benign cfa04110=Cell cycle.cfa04115=p53 signaling pathway.cfa04210=Apoptosis.cfa05166=HTLV-I infection
|
|
|
272 Contig110_chr20_47192181_47193618 93 chr20 47192262 ENSCAFT00000023054 ENSCAFP00000021407 A 308 P 484814 probably damaging N
|
|
|
273 Contig9_chr4_26730063_26730585 245 chr4 26730316 ENSCAFT00000023087 ENSCAFP00000021437 E 153 D 489044 benign N
|
|
|
274 Contig1_chr34_35420831_35421658 73 chr34 35420908 ENSCAFT00000023111 ENSCAFP00000021457 V 251 I 488144 benign N
|
|
|
275 Contig199_chr2_79696091_79697603 751 chr2 79696840 ENSCAFT00000023253 ENSCAFP00000021593 D 54 A U possibly damaging N
|
|
|
276 Contig146_chrX_38946913_38947473 307 chrX 38947225 ENSCAFT00000023268 ENSCAFP00000021608 L 160 V 612457 possibly damaging N
|
|
|
277 Contig63_chr9_23532151_23533554 1297 chr9 23533421 ENSCAFT00000023438 ENSCAFP00000021767 Q 279 R 490958 benign N
|
|
|
278 Contig89_chr5_32060784_32061151 293 chr5 32061079 ENSCAFT00000023913 ENSCAFP00000022199 W 106 * 489430 probably damaging N
|
|
|
279 Contig15_chr3_65640843_65642155 1100 chr3 65641942 ENSCAFT00000023933 ENSCAFP00000022218 V 383 A 479080 benign N
|
|
|
280 Contig49_chr26_33571748_33572620 689 chr26 33572452 ENSCAFT00000024062 ENSCAFP00000022339 R 478 W 486440 benign N
|
|
|
281 Contig96_chr20_48055741_48057197 524 chr20 48056259 ENSCAFT00000024100 ENSCAFP00000022374 R 172 Q U benign N
|
|
|
282 Contig104_chr20_48062263_48062546 210 chr20 48062492 ENSCAFT00000024100 ENSCAFP00000022374 V 775 G U probably damaging N
|
|
|
283 Contig33_chr37_28794567_28796956 2144 chr37 28796718 ENSCAFT00000024137 ENSCAFP00000022408 E 279 Q 488536 benign N
|
|
|
284 Contig24_chr7_32005266_32005660 212 chr7 32005479 ENSCAFT00000024154 ENSCAFP00000022424 T 92 M U probably damaging N
|
|
|
285 Contig174_chr18_56896461_56897594 274 chr18 56896734 ENSCAFT00000024637 ENSCAFP00000022858 V 157 L 483779 benign cfa04130=SNARE interactions in vesicular transport
|
|
|
286 Contig55_chr20_48811642_48812027 299 chr20 48811941 ENSCAFT00000024761 ENSCAFP00000022970 H 993 R 476678 benign N
|
|
|
287 Contig220_chr18_56925351_56927006 920 chr18 56926246 ENSCAFT00000024787 ENSCAFP00000022995 P 420 Q 476051 possibly damaging cfa03022=Basal transcription factors.cfa05168=Herpes simplex infection
|
|
|
288 Contig12_chr8_39044824_39045409 359 chr8 39045181 ENSCAFT00000024804 ENSCAFP00000023011 I 280 T 612894 possibly damaging N
|
|
|
289 Contig23_chr3_72567678_72570858 1313 chr3 72568976 ENSCAFT00000024846 ENSCAFP00000023051 L 298 P 488826 benign N
|
|
|
290 Contig190_chr7_35896301_35896811 232 chr7 35896528 ENSCAFT00000024892 ENSCAFP00000023095 R 3 L 480092 unknown cfa00020=Citrate cycle (TCA cycle).cfa01100=Metabolic pathways.cfa05200=Pathways in cancer.cfa05211=Renal cell carcinoma
|
|
|
291 Contig119_chr20_49114009_49114654 266 chr20 49114270 ENSCAFT00000024934 ENSCAFP00000023135 F 339 L 484849 benign N
|
|
|
292 Contig47_chr8_41487304_41487682 210 chr8 41487515 ENSCAFT00000025088 ENSCAFP00000023286 S 1743 L 490729 possibly damaging N
|
|
|
293 Contig67_chr2_84099157_84100880 345 chr2 84099493 ENSCAFT00000025109 ENSCAFP00000023307 I 60 L U benign N
|
|
|
294 Contig33_chr20_49727730_49730958 2192 chr20 49729935 ENSCAFT00000025308 ENSCAFP00000023495 T 448 R U probably damaging N
|
|
|
295 Contig33_chr20_49727730_49730958 2907 chr20 49730606 ENSCAFT00000025308 ENSCAFP00000023495 W 493 L U benign N
|
|
|
296 Contig93_chr8_42181027_42183022 694 chr8 42181716 ENSCAFT00000025462 ENSCAFP00000023641 L 782 P U benign N
|
|
|
297 Contig131_chrX_44937490_44940040 950 chrX 44938456 ENSCAFT00000025663 ENSCAFP00000023835 V 120 M 491894 benign N
|
|
|
298 Contig100_chrX_44915404_44918232 1832 chrX 44917224 ENSCAFT00000025663 ENSCAFP00000023835 R 1212 Q 491894 benign N
|
|
|
299 Contig100_chrX_44915404_44918232 920 chrX 44916331 ENSCAFT00000025663 ENSCAFP00000023835 L 1377 V 491894 benign N
|
|
|
300 Contig123_chr9_26132942_26133532 310 chr9 26133253 ENSCAFT00000025948 ENSCAFP00000024090 I 232 V 491022 benign N
|
|
|
301 Contig34_chr6_17772839_17773548 489 chr6 17773329 ENSCAFT00000026008 ENSCAFP00000024146 E 377 Q U benign N
|
|
|
302 Contig382_chr7_43383655_43383893 190 chr7 43383854 ENSCAFT00000026053 ENSCAFP00000024188 R 123 C U possibly damaging N
|
|
|
303 Contig163_chr2_87404548_87404792 132 chr2 87404673 ENSCAFT00000026251 ENSCAFP00000024378 D 239 N U benign N
|
|
|
304 Contig15_chr3_91850893_91851323 75 chr3 91850967 ENSCAFT00000026343 ENSCAFP00000024465 S 722 N 595148 benign cfa04360=Axon guidance
|
|
|
305 Contig141_chr7_44385686_44386047 166 chr7 44385857 ENSCAFT00000026393 ENSCAFP00000024510 L 166 P 490412 benign cfa04810=Regulation of actin cytoskeleton
|
|
|
306 Contig161_chr2_87840986_87841705 540 chr2 87841516 ENSCAFT00000026485 ENSCAFP00000024598 F 678 C 478233 probably damaging cfa03018=RNA degradation
|
|
|
307 Contig177_chr9_27497479_27498192 354 chr9 27497831 ENSCAFT00000026613 ENSCAFP00000024719 A 175 V 491046 possibly damaging N
|
|
|
308 Contig162_chr6_20156115_20157725 81 chr6 20156197 ENSCAFT00000026687 ENSCAFP00000024793 T 702 M 489923.489924.607168 benign N
|
|
|
309 Contig8_chr9_28287278_28288276 469 chr9 28287755 ENSCAFT00000026707 ENSCAFP00000024813 A 75 P 491060 benign N
|
|
|
310 Contig166_chr7_45276673_45277595 235 chr7 45276916 ENSCAFT00000026881 ENSCAFP00000024984 V 525 I 490428 benign N
|
|
|
311 Contig16_chr8_51223078_51223662 481 chr8 51223563 ENSCAFT00000026967 ENSCAFP00000025070 R 869 Q 490790 benign N
|
|
|
312 Contig65_chr9_29792446_29793465 893 chr9 29793341 ENSCAFT00000027073 ENSCAFP00000025173 S 81 A 491082 benign N
|
|
|
313 Contig175_chr6_30926774_30927470 446 chr6 30927229 ENSCAFT00000027269 ENSCAFP00000025361 S 663 T 403453 benign cfa02010=ABC transporters.cfa04977=Vitamin digestion and absorption
|
|
|
314 Contig45_chr30_33024389_33025619 471 chr30 33024857 ENSCAFT00000027320 ENSCAFP00000025407 G 986 A 487608 benign N
|
|
|
315 Contig60_chr20_53087461_53088013 184 chr20 53087649 ENSCAFT00000027519 ENSCAFP00000025591 S 556 L 611163 benign N
|
|
|
316 Contig98_chr5_37073086_37073674 378 chr5 37073467 ENSCAFT00000027596 ENSCAFP00000025664 V 38 M 479499 probably damaging cfa04130=SNARE interactions in vesicular transport
|
|
|
317 Contig64_chr9_36235086_36235751 475 chr9 36235563 ENSCAFT00000027673 ENSCAFP00000025737 D 260 E 491111 benign cfa04970=Salivary secretion
|
|
|
318 Contig72_chr30_35330469_35330831 236 chr30 35330709 ENSCAFT00000027712 ENSCAFP00000025770 G 386 C 478353 probably damaging cfa04510=Focal adhesion.cfa04512=ECM-receptor interaction.cfa04810=Regulation of actin cytoskeleton.cfa05410=Hypertrophic cardiomyopathy (HCM).cfa05412=Arrhythmogenic right ventricular cardiomyopathy (ARVC).cfa05414=Dilated cardiomyopathy
|
|
|
319 Contig12_chr8_66066327_66066629 89 chr8 66066402 ENSCAFT00000027927 ENSCAFP00000025970 K 158 R 490836 benign N
|
|
|
320 Contig212_chr8_66173086_66174259 622 chr8 66173712 ENSCAFT00000027950 ENSCAFP00000025993 K 114 Q 480421 benign N
|
|
|
321 Contig176_chr7_48083671_48084458 311 chr7 48083983 ENSCAFT00000027972 ENSCAFP00000026015 R 128 H 480148 probably damaging N
|
|
|
322 Contig3_chr4_58820541_58821952 265 chr4 58820806 ENSCAFT00000027979 ENSCAFP00000026022 A 31 T 489166 benign N
|
|
|
323 Contig24_chr7_48238665_48239174 383 chr7 48239049 ENSCAFT00000028007 ENSCAFP00000026049 T 227 M 480151 probably damaging N
|
|
|
324 Contig25_chr6_26340448_26341519 657 chr6 26341104 ENSCAFT00000028115 ENSCAFP00000026155 S 128 L 479811 possibly damaging N
|
|
|
325 Contig212_chr5_38871122_38871621 302 chr5 38871429 ENSCAFT00000028231 ENSCAFP00000026253 P 2265 L 489507 benign N
|
|
|
326 Contig147_chr6_27310627_27310983 100 chr6 27310719 ENSCAFT00000028327 ENSCAFP00000026344 V 154 A U benign N
|
|
|
327 Contig160_chr6_27318582_27318861 67 chr6 27318647 ENSCAFT00000028327 ENSCAFP00000026344 K 325 R U benign N
|
|
|
328 Contig18_chr4_61023435_61026038 385 chr4 61023825 ENSCAFT00000028363 ENSCAFP00000026377 P 4110 L 479323 benign N
|
|
|
329 Contig162_chr30_40685605_40687049 343 chr30 40685956 ENSCAFT00000028463 ENSCAFP00000026472 A 416 P 487646 benign N
|
|
|
330 Contig68_chr20_54017481_54018354 221 chr20 54017705 ENSCAFT00000028500 ENSCAFP00000026509 W 539 R U benign N
|
|
|
331 Contig50_chr7_59076761_59079381 2353 chr7 59079104 ENSCAFT00000028551 ENSCAFP00000026557 V 1487 I 490492 benign N
|
|
|
332 Contig51_chr7_59079274_59084588 2611 chr7 59081905 ENSCAFT00000028551 ENSCAFP00000026557 A 575 V 490492 benign N
|
|
|
333 Contig3_chr20_54855789_54856135 37 chr20 54855833 ENSCAFT00000028813 ENSCAFP00000026796 F 6015 S U unknown N
|
|
|
334 Contig157_chr5_43472186_43472528 168 chr5 43472353 ENSCAFT00000028826 ENSCAFP00000026807 R 355 Q 489526 benign cfa00010=Glycolysis / Gluconeogenesis.cfa00340=Histidine metabolism.cfa00350=Tyrosine metabolism.cfa00360=Phenylalanine metabolism.cfa00410=beta-Alanine metabolism.cfa00980=Metabolism of xenobiotics by cytochrome P450.cfa00982=Drug metabolism - cytochrome P450.cfa01100=Metabolic pathways
|
|
|
335 Contig80_chr20_55281094_55281971 129 chr20 55281228 ENSCAFT00000028936 ENSCAFP00000026914 T 931 A U benign N
|
|
|
336 Contig214_chr8_74493164_74493474 188 chr8 74493346 ENSCAFT00000029054 ENSCAFP00000027017 R 94 C U probably damaging N
|
|
|
337 Contig259_chr20_55571618_55572503 186 chr20 55571803 ENSCAFT00000029100 ENSCAFP00000027059 K 526 Q 485001 benign N
|
|
|
338 Contig180_chr9_41668066_41668716 357 chr9 41668451 ENSCAFT00000029122 ENSCAFP00000027081 E 990 D 491145 benign cfa03410=Base excision repair
|
|
|
339 Contig61_chr4_63087183_63089623 491 chr4 63087672 ENSCAFT00000029130 ENSCAFP00000027089 A 20 S U benign N
|
|
|
340 Contig261_chrX_94412915_94414298 488 chrX 94413396 ENSCAFT00000029188 ENSCAFP00000027142 D 329 E U unknown N
|
|
|
341 Contig58_chr4_70221679_70223505 1749 chr4 70223432 ENSCAFT00000029501 ENSCAFP00000027423 T 324 S 403721 benign cfa04060=Cytokine-cytokine receptor interaction.cfa04080=Neuroactive ligand-receptor interaction.cfa04630=Jak-STAT signaling pathway
|
|
|
342 Contig21_chr7_77985141_77986170 827 chr7 77985962 ENSCAFT00000029651 ENSCAFP00000027557 A 855 S 490545 benign N
|
|
|
343 Contig93_chrX_104176429_104177974 811 chrX 104177246 ENSCAFT00000029709 ENSCAFP00000027610 T 719 M 492128 benign cfa03008=Ribosome biogenesis in eukaryotes
|
|
|
344 Contig175_chr9_46116277_46118268 1090 chr9 46117366 ENSCAFT00000029722 ENSCAFP00000027622 Q 693 H U benign N
|
|
|
345 Contig134_chr4_76495667_76496825 860 chr4 76496507 ENSCAFT00000029827 ENSCAFP00000027720 I 113 V 612589 benign cfa00250=Alanine, aspartate and glutamate metabolism.cfa00260=Glycine, serine and threonine metabolism.cfa01100=Metabolic pathways
|
|
|
346 Contig247_chr6_31967574_31967796 158 chr6 31967732 ENSCAFT00000029875 ENSCAFP00000027765 P 750 T 489999 benign N
|
|
|
347 Contig6_chr7_81650872_81657348 3786 chr7 81654636 ENSCAFT00000030050 ENSCAFP00000027927 S 501 C 480218 benign N
|
|
|
348 Contig122_chr5_57147596_57148457 360 chr5 57147964 ENSCAFT00000030140 ENSCAFP00000028007 T 713 I 479558 benign N
|
|
|
349 Contig83_chr20_58039274_58039724 380 chr20 58039649 ENSCAFT00000030192 ENSCAFP00000028056 E 142 K 611866 benign N
|
|
|
350 Contig42_chr5_58023274_58024296 585 chr5 58023845 ENSCAFT00000030282 ENSCAFP00000028135 V 415 A 489580 benign N
|
|
|
351 Contig248_chr20_58217741_58219717 751 chr20 58218495 ENSCAFT00000030285 ENSCAFP00000028138 G 278 S 485038 unknown N
|
|
|
352 Contig127_chr6_39501489_39501966 83 chr6 39501576 ENSCAFT00000030381 ENSCAFP00000028228 N 155 S 490020 benign N
|
|
|
353 Contig123_chr6_39499974_39501056 816 chr6 39500798 ENSCAFT00000030381 ENSCAFP00000028228 A 195 P 490020 benign N
|
|
|
354 Contig247_chr6_39576694_39577607 493 chr6 39577171 ENSCAFT00000030386 ENSCAFP00000028233 S 745 N 490021 benign N
|
|
|
355 Contig6_chr9_50725202_50725646 143 chr9 50725344 ENSCAFT00000030726 ENSCAFP00000028560 M 12 T 491218 benign N
|
|
|
356 Contig221_chr6_41879771_41881379 766 chr6 41880519 ENSCAFT00000030883 ENSCAFP00000028717 A 184 T 606755 benign N
|
|
|
357 Contig231_chr5_60474911_60475630 279 chr5 60475186 ENSCAFT00000030960 ENSCAFP00000028794 C 505 Y 489618 possibly damaging N
|
|
|
358 Contig99_chr5_63306202_63308496 2063 chr5 63308224 ENSCAFT00000031146 ENSCAFP00000028978 A 421 V U unknown N
|
|
|
359 Contig245_chr5_66149146_66149848 349 chr5 66149499 ENSCAFT00000031407 ENSCAFP00000029234 R 207 Q 479601 benign cfa00760=Nicotinate and nicotinamide metabolism.cfa01100=Metabolic pathways
|
|
|
360 Contig305_chr5_67253589_67254394 375 chr5 67253954 ENSCAFT00000031570 ENSCAFP00000029391 R 203 Q U possibly damaging N
|
|
|
361 Contig94_chr9_56873843_56875505 1578 chr9 56875408 ENSCAFT00000031743 ENSCAFP00000029555 P 2937 S U benign N
|
|
|
362 Contig107_chr5_71317862_71318113 71 chr5 71317944 ENSCAFT00000031781 ENSCAFP00000029590 M 281 V U benign N
|
|
|
363 Contig134_chr9_57426140_57427208 236 chr9 57426380 ENSCAFT00000031798 ENSCAFP00000029606 V 89 I 480698 benign cfa00590=Arachidonic acid metabolism.cfa01100=Metabolic pathways
|
|
|
364 Contig60_chr12_5631507_5632392 818 chr12 5632313 ENSCAFT00000031814 ENSCAFP00000029621 Y 1697 C 481734 unknown cfa04510=Focal adhesion.cfa04512=ECM-receptor interaction.cfa04974=Protein digestion and absorption.cfa05146=Amoebiasis
|
|
|
365 Contig132_chr5_73710776_73711271 149 chr5 73710927 ENSCAFT00000031848 ENSCAFP00000029653 T 1323 M 489696 probably damaging N
|
|
|
366 Contig39_chr9_59278364_59279024 398 chr9 59278757 ENSCAFT00000032068 ENSCAFP00000029863 A 957 T 480718 benign N
|
|
|
367 Contig177_chr9_61212763_61213621 700 chr9 61213430 ENSCAFT00000032171 ENSCAFP00000029958 D 79 N U benign N
|
|
|
368 Contig67_chr6_62507717_62510152 1055 chr6 62508787 ENSCAFT00000032186 ENSCAFP00000029972 I 212 M 479959 probably damaging cfa00380=Tryptophan metabolism.cfa00450=Selenocompound metabolism.cfa01100=Metabolic pathways
|
|
|
369 Contig66_chr6_64570039_64570630 325 chr6 64570365 ENSCAFT00000032239 ENSCAFP00000030024 A 862 G 479964 benign cfa04740=Olfactory transduction.cfa04972=Pancreatic secretion
|
|
|
370 Contig22_chr6_64809414_64810661 626 chr6 64810027 ENSCAFT00000032269 ENSCAFP00000030052 Q 559 K 490179 benign N
|
|
|
371 Contig50_chr5_85052459_85052865 55 chr5 85052515 ENSCAFT00000032431 ENSCAFP00000030201 S 32 G 479688 benign N
|
|
|
372 Contig25_chr5_85095840_85098495 1627 chr5 85097474 ENSCAFT00000032433 ENSCAFP00000030203 F 681 S U benign N
|
|
|
373 Contig25_chr5_85480673_85480982 186 chr5 85480860 ENSCAFT00000032493 ENSCAFP00000030260 A 180 T 610026 possibly damaging cfa05010=Alzheimer's disease
|
|
|
374 Contig19_chr5_24601128_24602241 685 chr5 24601813 ENSCAFT00000035141 ENSCAFP00000030364 T 695 S U benign N
|
|
|
375 Contig59_chr26_11519273_11520242 659 chr26 11519937 ENSCAFT00000035276 ENSCAFP00000030520 P 160 L 403557 probably damaging cfa03015=mRNA surveillance pathway.cfa04114=Oocyte meiosis.cfa04270=Vascular smooth muscle contraction.cfa04510=Focal adhesion.cfa04720=Long-term potentiation.cfa04728=Dopaminergic synapse.cfa04810=Regulation of actin cytoskeleton.cfa04910=Insulin signaling pathway.cfa05168=Herpes simplex infection
|
|
|
376 Contig27_chr12_23130802_23131771 353 chr12 23131154 ENSCAFT00000035307 ENSCAFP00000030552 V 565 M 474935 probably damaging N
|
|
|
377 Contig31_chr1_8052327_8053606 234 chr1 8052570 ENSCAFT00000035442 ENSCAFP00000030703 C 153 S U possibly damaging N
|
|
|
378 Contig59_chr20_40539078_40540678 1223 chr20 40540302 ENSCAFT00000035532 ENSCAFP00000030804 H 285 R 403502 benign cfa04620=Toll-like receptor signaling pathway.cfa05142=Chagas disease (American trypanosomiasis).cfa05143=African trypanosomiasis.cfa05144=Malaria.cfa05152=Tuberculosis.cfa05162=Measles.cfa05168=Herpes simplex infection
|
|
|
379 Contig152_chr6_25356961_25358151 701 chr6 25357665 ENSCAFT00000035750 ENSCAFP00000031044 P 479 S 608555 benign cfa04142=Lysosome
|
|
|
380 Contig18_chr9_58576258_58576773 215 chr9 58576474 ENSCAFT00000035914 ENSCAFP00000031224 K 118 E 480706 benign N
|
|
|
381 Contig8_chr15_38734005_38734403 242 chr15 38734244 ENSCAFT00000035916 ENSCAFP00000031226 A 237 V 611996 possibly damaging N
|
|
|
382 Contig76_chr3_30625909_30626247 159 chr3 30626069 ENSCAFT00000036198 ENSCAFP00000031549 T 135 S 479171 benign cfa00260=Glycine, serine and threonine metabolism.cfa00270=Cysteine and methionine metabolism.cfa01100=Metabolic pathways
|
|
|
383 Contig86_chr37_14528768_14530343 873 chr37 14529628 ENSCAFT00000036570 ENSCAFP00000031969 V 738 D 478875.609202 possibly damaging cfa04060=Cytokine-cytokine receptor interaction.cfa04350=TGF-beta signaling pathway
|
|
|
384 Contig9_chr5_54124181_54125739 1134 chr5 54125291 ENSCAFT00000036640 ENSCAFP00000032043 A 187 T 610286 benign N
|
|
|
385 Contig107_chr9_8990420_8991676 1178 chr9 8991591 ENSCAFT00000036774 ENSCAFP00000032186 T 55 M 483288 benign N
|
|
|
386 Contig47_chr12_20319418_20320775 1212 chr12 20320622 ENSCAFT00000036825 ENSCAFP00000032241 K 606 T 474930 benign cfa00280=Valine, leucine and isoleucine degradation.cfa00630=Glyoxylate and dicarboxylate metabolism.cfa00640=Propanoate metabolism.cfa01100=Metabolic pathways
|
|
|
387 Contig4_chr2_45195542_45196115 233 chr2 45195785 ENSCAFT00000037022 ENSCAFP00000032463 D 833 N 478055 possibly damaging N
|
|
|
388 Contig8_chr8_77227029_77227651 339 chr8 77227366 ENSCAFT00000037096 ENSCAFP00000032544 T 61 A 490895.612602 benign cfa04020=Calcium signaling pathway.cfa04145=Phagosome.cfa04640=Hematopoietic cell lineage.cfa04650=Natural killer cell mediated cytotoxicity.cfa04662=B cell receptor signaling pathway.cfa04664=Fc epsilon RI signaling pathway.cfa04666=Fc gamma R-mediated phagocytosis.cfa04672=Intestinal immune network for IgA production.cfa05140=Leishmaniasis.cfa05143=African trypanosomiasis.cfa05146=Amoebiasis.cfa05150=Staphylococcus aureus infection.cfa05152=Tuberculosis.cfa05162=Measles.cfa05310=Asthma.cfa05320=Autoimmune thyroid disease.cfa05322=Systemic lupus erythematosus.cfa05323=Rheumatoid arthritis.cfa05330=Allograft rejection.cfa05340=Primary immunodeficiency.cfa05414=Dilated cardiomyopathy.cfa05416=Viral myocarditis
|
|
|
389 Contig2_chr7_60049092_60051693 266 chr7 60049361 ENSCAFT00000038176 ENSCAFP00000033857 T 195 M U probably damaging N
|
|
|
390 Contig31_chr30_24179816_24187402 4867 chr30 24184686 ENSCAFT00000038211 ENSCAFP00000033897 G 103 S U benign N
|
|
|
391 Contig9_chr27_48250956_48251793 192 chr27 48251161 ENSCAFT00000038256 ENSCAFP00000033944 T 166 M 477739 probably damaging N
|
|
|
392 Contig45_chr27_43537046_43537944 568 chr27 43537599 ENSCAFT00000038301 ENSCAFP00000033996 M 69 I 611773 benign cfa04010=MAPK signaling pathway.cfa04810=Regulation of actin cytoskeleton.cfa05200=Pathways in cancer.cfa05218=Melanoma
|
|
|
393 Contig133_chr18_28371600_28372547 83 chr18 28371695 ENSCAFT00000038383 ENSCAFP00000034090 L 102 Q 475933 probably damaging N
|
|
|
394 Contig11_chr28_8532951_8533892 511 chr28 8533462 ENSCAFT00000038937 ENSCAFP00000034728 R 19 C 477763 probably damaging cfa03008=Ribosome biogenesis in eukaryotes.cfa03013=RNA transport
|
|
|
395 Contig1_chr14_5733966_5735336 783 chr14 5734754 ENSCAFT00000039094 ENSCAFP00000034905 A 166 T U benign N
|
|
|
396 Contig48_chr27_6001075_6001818 392 chr27 6001478 ENSCAFT00000039109 ENSCAFP00000034919 R 103 H U probably damaging N
|
|
|
397 Contig40_chr11_43589173_43590288 973 chr11 43590138 ENSCAFT00000039148 ENSCAFP00000034962 R 1617 P 481557 benign N
|
|
|
398 Contig1_chr14_30424688_30425258 179 chr14 30424861 ENSCAFT00000039390 ENSCAFP00000035239 T 648 I 475245 benign cfa04666=Fc gamma R-mediated phagocytosis.cfa04810=Regulation of actin cytoskeleton
|
|
|
399 Contig58_chr8_7461111_7462065 323 chr8 7461423 ENSCAFT00000039451 ENSCAFP00000035309 L 112 F U benign N
|
|
|
400 Contig1_chr25_43094809_43095852 908 chr25 43095708 ENSCAFT00000039609 ENSCAFP00000035483 W 18 G U unknown N
|
|
|
401 Contig114_chr25_43076436_43076800 141 chr25 43076581 ENSCAFT00000039609 ENSCAFP00000035483 S 45 C U unknown N
|
